Ionis Pharmaceuticals INC Form 4 insider transactions

Director Michael R. Hayden received stock options and restricted stock units from Ionis Pharmaceuticals as part of the company's Non-Employee Director Compensation Policy.

Director Allene M. Diaz received stock options and restricted stock units from Ionis Pharmaceuticals on July 1, 2024, as part of the company's non-employee director compensation policy.

Director Spencer R. Berthelsen received stock options and restricted stock units from Ionis Pharmaceuticals as part of their non-employee director compensation policy.

Director Spencer R. Berthelsen exercised stock options and sold shares of Ionis Pharmaceuticals on June 17, 2024, according to a Form 4 filing.

Director Joseph H. Wender exercised stock options for 16,000 shares of Ionis Pharmaceuticals (IONS) nearing their expiration date.

Director Joseph Klein III of Ionis Pharmaceuticals sold shares of common stock on May 3, 2024, through multiple transactions at varying prices.

EVP and Chief Business Officer of Ionis Pharmaceuticals, Joseph Baroldi, reports exercising stock options and selling shares to cover tax obligations.

EVP Brian Birchler of Ionis Pharmaceuticals reports acquisition and disposal of common stock and restricted stock units.

EVP, Chf GL Pdt Str Ofcr Kyle Jenne acquired 65,203 non-qualified stock options in Ionis Pharmaceuticals on February 26, 2024.

Eric Swayze, an officer at Ionis Pharmaceuticals, acquired 605 shares of common stock through the company's employee stock purchase plan at a price of $34.425 per share.

CEO Brett P. Monia acquired 538 shares of Ionis Pharmaceuticals common stock through the company's employee stock purchase plan on February 29, 2024.

Richard S. Geary, an officer at Ionis Pharmaceuticals, reports purchasing 604 shares of common stock at $34.425 per share through the company's employee stock purchase plan.

Brian Birchler, Vice President at Ionis Pharmaceuticals, reports purchasing 604 shares of common stock at $34.425 per share through the employee stock purchase plan.

C. Frank Bennett, an officer of Ionis Pharmaceuticals, reports purchasing 383 shares of common stock through the company's employee stock purchase plan on February 29, 2024.